| Deal value | $172M |
|---|---|
| Share of market cap | 5.7% |
Key highlights
- Public offering of 11,538,462 shares priced at $13.00 per share
- Underwriters fully exercised their option for an additional 1,730,769 shares
- Total gross proceeds reached approximately $172.5 million
- Estimated net proceeds of $161.8 million after fees and expenses
- Lead book-running managers included J.P. Morgan, TD Cowen, and Mizuho
What Is the Capital Raise?
SELLAS Life Sciences Group, Inc. has structured an underwritten public offering involving the sale of 11,538,462 shares of common stock. The offering was priced at $13.00 per share, a figure notably influenced by current market conditions for clinical-stage biotechnology firms. To accommodate excess demand, the company granted underwriters a 30-day option to purchase up to 1,730,769 additional shares, which was exercised in full at the time of pricing. This expansion brought total gross proceeds to approximately $172.5 million. The transaction is expected to close on November 20, 2026, pending the satisfaction of customary closing conditions.
Use of Proceeds
- Funding the continued clinical development of lead product candidate GPS
- Advancing the SLS009 small molecule CDK9 inhibitor program
- Supporting general corporate purposes and working capital requirements
- Addressing costs associated with ongoing late-stage clinical trials
Business Overview
Based in New York, SELLAS is a late-stage clinical biopharmaceutical company targeting a diverse range of cancer indications. Its primary asset, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein. GPS is being evaluated as both a monotherapy and in combination with other agents to treat hematologic malignancies and solid tumors. Additionally, the company is developing SLS009 for patients with acute myeloid leukemia who possess unfavorable prognostic factors. These programs represent the core of the company's efforts to address high unmet needs in oncology through novel therapeutic mechanisms.
Financial Context
Prior to this capital raise, SELLAS maintained a market capitalization of approximately $3.03 billion. The stock experienced significant volatility, reflected in a 17.21% decline on the day of the pricing announcement, which is typical for dilutive equity offerings in the biotech sector. Despite this daily dip, the ticker has demonstrated robust momentum with an 85.06% increase over the preceding week. The relative strength index stands at 60.2, indicating the stock remains within neutral technical territory. This capital influx provides a necessary liquidity cushion for intensive research expenditures and ongoing clinical milestones.
Down 8.1% since our story on 20 Nov: $14.86 when we broke it → $13.66 at the close on 20 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 21 Oct | $12.14 |
|---|---|
| 22 Oct | $11.35 |
| 23 Oct | $11.54 |
| 26 Oct | $11.34 |
| 27 Oct | $12.17 |
| 28 Oct | $10.38 |
| 29 Oct | $10.16 |
| 30 Oct | $9.68 |
| 2 Nov | $8.55 |
| 3 Nov | $8.87 |
| 4 Nov | $9.14 |
| 5 Nov | $7.88 |
| 6 Nov | $8.42 |
| 9 Nov | $8.58 |
| 10 Nov | $8.37 |
| 11 Nov | $8.42 |
| 12 Nov | $8.03 |
| 13 Nov | $7.86 |
| 16 Nov | $7.47 |
| 17 Nov | $19.15 |
| 18 Nov | $17.95 |
| 19 Nov | $14.86 |
| 20 Nov | $13.66 |
| Share price | $14.86 |
|---|---|
| Market cap | $3.0B |
| 1-month price change | +24.04% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by SELLAS Life Sciences Group, Inc. announcing the pricing of an underwritten public offering.
Track SELLAS Life Sciences Group, Inc. live
Get the next SELLAS Life Sciences Group, Inc. SEC filing seconds after it lands.




